Posted On: 12/14/2013 10:34:22 AM
Post# of 144784
$HPTX Headlines
2013 Biotech Watchlist Update: Companies Climb And Crumble On Catalysts 10:48 a.m. Nov. 1, 2013 - Seeking Alpha
Hyperion Therapeutics Grants Rights to Sobi to Distribute RAVICTI in Middle East 4:06 a.m. Oct. 1, 2013 - benzinga.com
Hyperion Presents Data on Ravicti - Analyst Blog 12:30 p.m. Sept. 5, 2013 - Zacks.com
Hyperion's Loss Narrows Y/Y - Analyst Blog 12:07 p.m. Aug. 20, 2013 - Zacks.com
10-Q/A: HYPERION THERAPEUTICS INC 4:10 p.m. Aug. 15, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: HYPERION THERAPEUTICS INC 4:24 p.m. Aug. 14, 2013 - Edgar Online - (EDG = 10Q, 10K)
Hyperion Therapeutics Announces Ashley Gould as Chief Legal Officer 2:14 p.m. July 17, 2013 - benzinga.com
Data from Hyperion's UCD Drugs - Analyst Blog 6:30 p.m. June 24, 2013 - Zacks.com
Hyperion Acquires Buphenyl Rights - Analyst Blog 4:35 p.m. June 10, 2013 - Zacks.com
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential 9:18 p.m. May 3, 2013 - Seeking Alpha
5 Biotechnology Stocks That Greatly Outperformed The Market In Q1 3:12 a.m. April 15, 2013 - Seeking Alpha
Hyperion Therapeutics Closes Follow-On Offering, Underwriters' Exercised Option 2:07 p.m. March 13, 2013 - benzinga.com
10-K/A: HYPERION THERAPEUTICS INC 2:32 p.m. Feb. 26, 2013 - Edgar Online - (EDG = 10Q, 10K)
Best-Performing Russell 3000 Stocks Year To Date 6:38 p.m. Feb. 11, 2013 - Seeking Alpha
Biotech Movers: A Doubler for Opexa 2:30 a.m. Feb. 11, 2013 - InvestorPlace.com
4 Healthcare Stock Stories for Tuesday Wellness 7:20 p.m. Feb. 5, 2013 - Wall St. Cheat Sheet
Hyperion Confirms FDA Approval for RAVICITI 2:02 p.m. Feb. 1, 2013 - benzinga.com
Market Bets On Approval For Hyperion's Ravicti On FDA's 'Hint' 1:07 p.m. Jan. 24, 2013 - Seeking Alpha
FDA Will Not Meet PDUFA Date for Hyperion's Ravicti 7:59 a.m. Jan. 16, 2013 - benzinga.com
Hyperion's Drug Ravicti Likely To Receive FDA Approval 11:30 a.m. Jan. 9, 2013 - Seeking Alpha
Hyperion Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference 4:05 p.m. Nov. 26, 2013 - GlobeNewswire
Hyperion Therapeutics to Present at the Jefferies 2013 London Healthcare Conference 9:00 a.m. Nov. 15, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Third Quarter 2013 Financial Results 4:06 p.m. Nov. 12, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Third Quarter 2013 Financial Results Teleconference and Webcast 9:00 a.m. Nov. 6, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Initiation of THRIVE Study, a Long-Term Registry of Patients With Urea Cycle Disorders 8:00 a.m. Oct. 31, 2013 - GlobeNewswire
Sobi Gains Rights to Distribute RAVICTI(R) on a Named Patient Use Basis in Middle East From Hyperion Therapeutics, Inc. 6:00 a.m. Oct. 1, 2013 - GlobeNewswire
Sobi gains rights to distribute RAVICTI(R) on a named patient use basis in Middle East from Hyperion Therapeutics, Inc. 1:07 a.m. Oct. 1, 2013 - GlobeNewswire
Sobi gains rights to distribute RAVICTI® on a named patient use basis in Middle East from Hyperion Therapeutics, Inc. 1:02 a.m. Oct. 1, 2013 - Thomson Reuters ONE
Hyperion Therapeutics to Present at the Leerink Swann Rare Disease Day 8:01 a.m. Sept. 26, 2013 - GlobeNewswire
Hyperion Therapeutics to Present at the Annual Stifel 2013 Healthcare Conference 3:30 p.m. Sept. 5, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Presentation of Long Term Data on Ammonia Control in Pediatric Patients Treated With RAVICTI(R) at the 12th International Congress of Inborn Errors of Metabolism and the Urea Cycle Disorder Satellite Symposium 7:00 a.m. Sept. 3, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Second Quarter 2013 Financial Results 3:05 p.m. Aug. 14, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Second Quarter 2013 Financial Results Teleconference and Webcast 3:30 p.m. Aug. 8, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Larry J. Singer as Vice President, Manufacturing 8:15 a.m. Aug. 6, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Three New Additions to Its Senior Leadership Team 3:05 p.m. July 17, 2013 - GlobeNewswire
R&D Milestones, Response on Published Reports, and Independent Clinical Programs Widen Growth Opportunities for Biotech Companies - Research Report on Verastem, Acorda, Hyperion, XOMA, and Lexicon 7:00 a.m. July 3, 2013 - PR Newswire
Hyperion Therapeutics to Present at the Eighth Annual JMP 2013 Global Healthcare Securities Conference 8:00 a.m. July 2, 2013 - GlobeNewswire
Wall Street Fundamentals Releases New In-Depth Stock Reports on CHTP, CLVS, HPTX and SGEN 7:32 a.m. June 28, 2013 - ACCESSWIRE
Hyperion Therapeutics Announces RAVICTI and BUPHENYL Pharmacokinetic Analyses Reported in The Journal of Clinical Pharmacology 7:12 a.m. June 18, 2013 - GlobeNewswire
Hyperion Therapeutics Acquires Worldwide Rights to BUPHENYL 8:01 a.m. June 3, 2013 - GlobeNewswire
2013 Biotech Watchlist Update: Companies Climb And Crumble On Catalysts 10:48 a.m. Nov. 1, 2013 - Seeking Alpha
Hyperion Therapeutics Grants Rights to Sobi to Distribute RAVICTI in Middle East 4:06 a.m. Oct. 1, 2013 - benzinga.com
Hyperion Presents Data on Ravicti - Analyst Blog 12:30 p.m. Sept. 5, 2013 - Zacks.com
Hyperion's Loss Narrows Y/Y - Analyst Blog 12:07 p.m. Aug. 20, 2013 - Zacks.com
10-Q/A: HYPERION THERAPEUTICS INC 4:10 p.m. Aug. 15, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: HYPERION THERAPEUTICS INC 4:24 p.m. Aug. 14, 2013 - Edgar Online - (EDG = 10Q, 10K)
Hyperion Therapeutics Announces Ashley Gould as Chief Legal Officer 2:14 p.m. July 17, 2013 - benzinga.com
Data from Hyperion's UCD Drugs - Analyst Blog 6:30 p.m. June 24, 2013 - Zacks.com
Hyperion Acquires Buphenyl Rights - Analyst Blog 4:35 p.m. June 10, 2013 - Zacks.com
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential 9:18 p.m. May 3, 2013 - Seeking Alpha
5 Biotechnology Stocks That Greatly Outperformed The Market In Q1 3:12 a.m. April 15, 2013 - Seeking Alpha
Hyperion Therapeutics Closes Follow-On Offering, Underwriters' Exercised Option 2:07 p.m. March 13, 2013 - benzinga.com
10-K/A: HYPERION THERAPEUTICS INC 2:32 p.m. Feb. 26, 2013 - Edgar Online - (EDG = 10Q, 10K)
Best-Performing Russell 3000 Stocks Year To Date 6:38 p.m. Feb. 11, 2013 - Seeking Alpha
Biotech Movers: A Doubler for Opexa 2:30 a.m. Feb. 11, 2013 - InvestorPlace.com
4 Healthcare Stock Stories for Tuesday Wellness 7:20 p.m. Feb. 5, 2013 - Wall St. Cheat Sheet
Hyperion Confirms FDA Approval for RAVICITI 2:02 p.m. Feb. 1, 2013 - benzinga.com
Market Bets On Approval For Hyperion's Ravicti On FDA's 'Hint' 1:07 p.m. Jan. 24, 2013 - Seeking Alpha
FDA Will Not Meet PDUFA Date for Hyperion's Ravicti 7:59 a.m. Jan. 16, 2013 - benzinga.com
Hyperion's Drug Ravicti Likely To Receive FDA Approval 11:30 a.m. Jan. 9, 2013 - Seeking Alpha
Hyperion Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference 4:05 p.m. Nov. 26, 2013 - GlobeNewswire
Hyperion Therapeutics to Present at the Jefferies 2013 London Healthcare Conference 9:00 a.m. Nov. 15, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Third Quarter 2013 Financial Results 4:06 p.m. Nov. 12, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Third Quarter 2013 Financial Results Teleconference and Webcast 9:00 a.m. Nov. 6, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Initiation of THRIVE Study, a Long-Term Registry of Patients With Urea Cycle Disorders 8:00 a.m. Oct. 31, 2013 - GlobeNewswire
Sobi Gains Rights to Distribute RAVICTI(R) on a Named Patient Use Basis in Middle East From Hyperion Therapeutics, Inc. 6:00 a.m. Oct. 1, 2013 - GlobeNewswire
Sobi gains rights to distribute RAVICTI(R) on a named patient use basis in Middle East from Hyperion Therapeutics, Inc. 1:07 a.m. Oct. 1, 2013 - GlobeNewswire
Sobi gains rights to distribute RAVICTI® on a named patient use basis in Middle East from Hyperion Therapeutics, Inc. 1:02 a.m. Oct. 1, 2013 - Thomson Reuters ONE
Hyperion Therapeutics to Present at the Leerink Swann Rare Disease Day 8:01 a.m. Sept. 26, 2013 - GlobeNewswire
Hyperion Therapeutics to Present at the Annual Stifel 2013 Healthcare Conference 3:30 p.m. Sept. 5, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Presentation of Long Term Data on Ammonia Control in Pediatric Patients Treated With RAVICTI(R) at the 12th International Congress of Inborn Errors of Metabolism and the Urea Cycle Disorder Satellite Symposium 7:00 a.m. Sept. 3, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Second Quarter 2013 Financial Results 3:05 p.m. Aug. 14, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Second Quarter 2013 Financial Results Teleconference and Webcast 3:30 p.m. Aug. 8, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Larry J. Singer as Vice President, Manufacturing 8:15 a.m. Aug. 6, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Three New Additions to Its Senior Leadership Team 3:05 p.m. July 17, 2013 - GlobeNewswire
R&D Milestones, Response on Published Reports, and Independent Clinical Programs Widen Growth Opportunities for Biotech Companies - Research Report on Verastem, Acorda, Hyperion, XOMA, and Lexicon 7:00 a.m. July 3, 2013 - PR Newswire
Hyperion Therapeutics to Present at the Eighth Annual JMP 2013 Global Healthcare Securities Conference 8:00 a.m. July 2, 2013 - GlobeNewswire
Wall Street Fundamentals Releases New In-Depth Stock Reports on CHTP, CLVS, HPTX and SGEN 7:32 a.m. June 28, 2013 - ACCESSWIRE
Hyperion Therapeutics Announces RAVICTI and BUPHENYL Pharmacokinetic Analyses Reported in The Journal of Clinical Pharmacology 7:12 a.m. June 18, 2013 - GlobeNewswire
Hyperion Therapeutics Acquires Worldwide Rights to BUPHENYL 8:01 a.m. June 3, 2013 - GlobeNewswire
(0)
(0)Scroll down for more posts ▼
